Sign in
Taking peoplePhase 4

Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-Acetylcysteine

Key facts

Who runs it
Theis S. Itenov
Where
Denmark1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
360 people, planned
Started
7 Sept 2026
Expected to end
Jul 2028
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • N-Acetylcysteine (NAC) Treatment
Record updated
16 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age ≥18 years
  • Documented clinical suspicion of infection
  • Model for end-stage liver disease (MELD) score ≥9

Who cannot take part

  • Any previous severe anaphylaxis
  • Ongoing treatment with N-acetylcysteine at randomization
  • Ongoing treatment with nitroglycerin
  • Other known allergy to N-acetylcysteine
  • Involuntary admission under the psychiatric law
  • Any other condition deemed by the investigator to compromise patient safety or trial integrity (e.g., severe coagulopathy, uncontrolled bleeding, diabetic ketoacidosis)
  • Admitted to hospital >24 hours before randomization
  • Documented clinical suspicion of bile duct obstruction
  • Refractory circulatory shock
  • Informed consent not obtainable
  • Inability to read and understand Danish to a degree that allows valid informed consent and completion of trial assessments
  • Expected initiation of palliative care within 48 hours of randomization

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objective of the IMPACT-NAC trial is to assess the effects of N-acetylcysteine on survival and hospital length of stay in adults admitted to the emergency department with acute infection or sepsis and evidence of liver dysfunction.

Read full original descriptionShow less

The main question it aims to answer is: does N-acetylcysteine increase the number of days alive and out of the hospital within the first 14 days after enrolment in the trial?

To answer this question, we will conduct a randomized, double-blinded controlled trial of 360 participants.

Participants will be randomized to either N-acetylcysteine or placebo (normal saline without active drugs). This will be administered as an infusion during four hours within the first day of hospital admission.

The 2 groups in the trial

  • N-acetylcysteineTreatment being tested

    Treatment: N-Acetylcysteine (NAC) Treatment

  • Placebo (normal saline)No study treatment, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Randomized, Placebo-controlled, Blinded, Parallel-group Clinical Trial to Assess the Efficacy of N-acetylcysteine in Adults With Acute Infections or Sepsis and Evidence of Liver Dysfunction: the IMPACT-NAC Trial
Record updated
16 September 2026